ZA971733B - Serine protease inhibitors. - Google Patents

Serine protease inhibitors.

Info

Publication number
ZA971733B
ZA971733B ZA9701733A ZA971733A ZA971733B ZA 971733 B ZA971733 B ZA 971733B ZA 9701733 A ZA9701733 A ZA 9701733A ZA 971733 A ZA971733 A ZA 971733A ZA 971733 B ZA971733 B ZA 971733B
Authority
ZA
South Africa
Prior art keywords
protease inhibitors
serine protease
serine
inhibitors
protease
Prior art date
Application number
ZA9701733A
Other languages
English (en)
Inventor
Anton Egbert Peter Adang
Jacobus Albertus Maria Peters
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Publication of ZA971733B publication Critical patent/ZA971733B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/022—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/022—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2
    • C07K5/0222—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2 with the first amino acid being heterocyclic, e.g. Pro, Trp
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06104—Dipeptides with the first amino acid being acidic
    • C07K5/06113—Asp- or Asn-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
ZA9701733A 1996-03-01 1997-02-27 Serine protease inhibitors. ZA971733B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP96200545 1996-03-01

Publications (1)

Publication Number Publication Date
ZA971733B true ZA971733B (en) 1997-09-10

Family

ID=8223738

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9701733A ZA971733B (en) 1996-03-01 1997-02-27 Serine protease inhibitors.

Country Status (22)

Country Link
US (1) US6218365B1 (cs)
EP (1) EP1012164B1 (cs)
JP (1) JP2000506838A (cs)
KR (1) KR19990087416A (cs)
CN (1) CN1212705A (cs)
AR (1) AR006311A1 (cs)
AT (1) ATE277074T1 (cs)
AU (1) AU715765B2 (cs)
BR (1) BR9707812A (cs)
CA (1) CA2246722A1 (cs)
CZ (1) CZ277998A3 (cs)
DE (1) DE69730871D1 (cs)
HU (1) HUP9901503A3 (cs)
ID (2) ID16104A (cs)
IL (1) IL120311A (cs)
NO (1) NO983992L (cs)
NZ (1) NZ331486A (cs)
PL (1) PL328665A1 (cs)
TR (1) TR199801705T2 (cs)
TW (1) TW523513B (cs)
WO (1) WO1997031939A1 (cs)
ZA (1) ZA971733B (cs)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001525823A (ja) 1997-05-15 2001-12-11 イーライ・リリー・アンド・カンパニー 抗血栓化合物
US6344450B1 (en) * 1999-02-09 2002-02-05 Bristol-Myers Squibb Company Lactam compounds and their use as inhibitors of serine proteases and method
EP1165601A2 (de) 1999-04-09 2002-01-02 Basf Aktiengesellschaft Prodrugs von thrombininhibitoren
AU2002222933A1 (en) * 2000-07-13 2002-01-30 Millennium Pharamaceuticals, Inc. Inhibitors of factor xa
EP1358178A2 (en) 2001-01-30 2003-11-05 Bristol-Myers Squibb Company Sulfonamide lactam inhibitors of factor xa
US6716869B2 (en) 2001-12-17 2004-04-06 Pharmacia Corporation Protease inhibitors of the coagulation cascade isolated from Dysidea sponges
JP2005519098A (ja) * 2002-03-01 2005-06-30 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 変形性関節症の治療方法
US7439226B2 (en) * 2003-09-30 2008-10-21 The United States Of America As Represented By The Department Of Health And Human Services Serine protease inhibitors
JP2008521853A (ja) * 2004-12-02 2008-06-26 プロビオドルグ エージー 神経疾患治療用の新規化合物
WO2007137080A2 (en) 2006-05-23 2007-11-29 Irm Llc Compounds and compositions as channel activating protease inhibitors
PT2019837E (pt) * 2006-05-23 2011-07-05 Irm Llc Compostos e composições como inibidores das proteases activadoras de canal
EP2117537A1 (en) 2007-02-09 2009-11-18 Irm Llc Compounds and compositions as channel activating protease inhibitors
EA200901082A1 (ru) * 2007-02-09 2010-02-26 Айрм Ллк Соединения и композиции в качестве ингибиторов протеазы, активирующей каналы
US10526315B2 (en) 2016-06-21 2020-01-07 Orion Ophthalmology LLC Carbocyclic prolinamide derivatives
FI3472149T3 (fi) 2016-06-21 2023-11-09 Orion Ophthalmology LLC Heterosyklisiä prolinamidijohdannaisia
DE102020103516B4 (de) 2020-02-11 2023-12-07 Universität Zu Lübeck Antivirale Wirkstoffe mit breiter Aktivität
US11124497B1 (en) 2020-04-17 2021-09-21 Pardes Biosciences, Inc. Inhibitors of cysteine proteases and methods of use thereof
JP2023530627A (ja) * 2020-06-09 2023-07-19 パルデス バイオサイエンシーズ， インコーポレイテッド システインプロテアーゼの阻害剤及びその使用方法
US11174231B1 (en) 2020-06-09 2021-11-16 Pardes Biosciences, Inc. Inhibitors of cysteine proteases and methods of use thereof
IL298324A (en) 2020-06-10 2023-01-01 Aligos Therapeutics Inc Anti-viral compounds for treating coronavirus, picornavirus, and norovirus infections
JP2024525589A (ja) 2021-07-09 2024-07-12 アリゴス セラピューティクス インコーポレイテッド 抗ウイルス化合物
US12065428B2 (en) 2021-09-17 2024-08-20 Aligos Therapeutics, Inc. Anti-viral compounds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69431718T2 (de) * 1993-04-30 2003-07-10 Merck & Co., Inc. Thrombin-inhibitoren
US5672582A (en) * 1993-04-30 1997-09-30 Merck & Co., Inc. Thrombin inhibitors
SE9301916D0 (sv) * 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
ZA951617B (en) * 1994-03-04 1997-02-27 Lilly Co Eli Antithrombotic agents.
WO1995035311A1 (en) * 1994-06-17 1995-12-28 Corvas International, Inc. 3-amino-2-oxo-1-piperidineacetic derivatives as enzyme inhibitors
JPH0820597A (ja) * 1994-07-07 1996-01-23 Meiji Seika Kaisha Ltd トロンビン阻害作用を有する複素環カルボニル化合物
CA2208772A1 (en) * 1994-12-22 1996-06-27 Benoit Bachand Low molecular weight bicyclic thrombin inhibitors
KR19990082424A (ko) * 1996-02-13 1999-11-25 이.에이치. 리링크 세린 프로테아제 억제제

Also Published As

Publication number Publication date
EP1012164A1 (en) 2000-06-28
JP2000506838A (ja) 2000-06-06
TR199801705T2 (xx) 1998-12-21
NO983992D0 (no) 1998-08-31
DE69730871D1 (de) 2004-10-28
AU715765B2 (en) 2000-02-10
NZ331486A (en) 1999-07-29
PL328665A1 (en) 1999-02-15
CZ277998A3 (cs) 1999-02-17
AU1795697A (en) 1997-09-16
ATE277074T1 (de) 2004-10-15
TW523513B (en) 2003-03-11
NO983992L (no) 1998-10-30
KR19990087416A (ko) 1999-12-27
CA2246722A1 (en) 1997-09-04
WO1997031939A1 (en) 1997-09-04
EP1012164B1 (en) 2004-09-22
IL120311A (en) 2001-10-31
CN1212705A (zh) 1999-03-31
AR006311A1 (es) 1999-08-25
US6218365B1 (en) 2001-04-17
IL120311A0 (en) 1997-06-10
BR9707812A (pt) 1999-07-27
ID16104A (id) 1997-09-04
HUP9901503A2 (hu) 1999-08-30
HUP9901503A3 (en) 2001-10-29
ID16105A (id) 1997-09-04

Similar Documents

Publication Publication Date Title
ZA992447B (en) Quinoxalinones as serine protease inhibitors.
ZA983629B (en) Serine protease inhibitors
ZA983843B (en) Protease inhibitors
AU7127298A (en) Serine protease inhibitors
HUP9901187A3 (en) Serine protease inhibitors
ZA992448B (en) Quinoxalinones as serine protease inhibitors.
ZA971733B (en) Serine protease inhibitors.
ZA983841B (en) Protease inhibitors
ZA971667B (en) Serine protease inhibitors.
ZA983522B (en) Protease inhibitors
PL336856A1 (en) Protease inhibitors
EP1093367A4 (en) PROTEASE INHIBITORS
PL328223A1 (en) Aspartil protease inhibitors
ZA988479B (en) Protease inhibitors
EP1067894A4 (en) PROTHEASEINHIBITOREN
EP1079821A4 (en) PROTEASE INHIBITORS
GB9800817D0 (en) Serine protease inhibitors
ZA988064B (en) Protease inhibitors
GB9603217D0 (en) Serine protease inhibitors
EP1086083A4 (en) PROTEASE INHIBITORS
EP1140897A4 (en) PROTEASE INHIBITORS
EP0975612A4 (en) PROTEASE INHIBITORS
GB9613719D0 (en) Serine protease inhibitors
ZA971178B (en) Serine protease inhibitors.
HK1018958A (en) Serine protease inhibitors